Vericel
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 314
- Market Cap
- $2.6B
- Introduction
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Want to stay updated on the latest news?
Curevo Vaccine, Myriad Genetics, Vericel Corporation, and CRISPR Therapeutics will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. PacBio ships Vega systems to Berry Genomics. PrognomiQ appoints Joel Kaufman as CFO. Vor Bio appoints Erez Kalir to its Board.
Stem Cell Therapy Market to Triple in Value, Reaching USD 52.1
The global stem cell therapy market is projected to grow from USD16.7 billion in 2024 to USD52.1 billion by 2034, at a CAGR of 12.1%. This growth is driven by advancements in regenerative medicine, increasing demand for minimally invasive treatments, and significant investments in research and development.
Zelsuvmi approval tops this year's most-read FDA approvals in dermatology
Zelsuvmi's approval for molluscum contagiosum tops Healio's most-read FDA approvals in dermatology for 2024, with other notable approvals including Xeomin, Klisyri, Zoryve, and more.
Human Osteoblasts Market Size to Surpass USD 90.71 Million by 2034
The human osteoblasts market is projected to grow from USD 48.74 million in 2024 to USD 90.71 million by 2034, driven by the aging population. North America dominated in 2023, while Asia-Pacific is expected to grow fastest. Key segments include human cell culture, regeneration surgeries, and hospitals. AI and tissue engineering advancements offer growth opportunities, despite challenges like a lack of skilled professionals.
United States Translational Regenerative Medicine Market By Application
The U.S. Translational Regenerative Medicine Market is projected to grow from USD xx.x Billion in 2023 to USD xx.x Billion by 2031, with a CAGR of xx.x%. Key applications include orthopedics, cardiovascular, oncology, wound healing, and others. Major manufacturers include Athersys, Avita Medical, AxoGen, and more. The market's future is promising yet complex, with regional variations and emerging trends.
FDA Approves Arthroscopic Knee Cartilage Repair
FDA approves arthroscopic delivery of MACI®, an autologous cultured chondrocytes on porcine collagen membrane, for knee cartilage defect repair, offering a less invasive option for patients.
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
Vericel announces FDA approval of NexoBrid for pediatric severe thermal burns, offering a non-surgical eschar removal solution.
© Copyright 2025. All Rights Reserved by MedPath